Conflicting results from anti-TNF trials in sepsis patients suggest that timely administration of TNF inhibitor drugs is crucial.
Heumann D. & Glauser M.P. Pathogenesis of sepsis. Sci. Am. Med. 1, 28–37 (1994).
Dellinger, R.P. et al. From the bench to the bedside: The future of sepsis research. Chest 111, 744–753 (1997).
Abraham E. et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277, 1531–1538 (1997).
Van Zee K.J. et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-lg fusion protein, Ro 45-2081. J. Immunol. 156, 2221–2230 (1996).
Cohen, J., Heumann D. & Glauser M.P. Do monoclonal antibodies and anticytokines still have a future in infectious diseases. Am. J. Med. 99, 45S–52S (1995).
Lesslauer, W. et al. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality. Eur. J. Immunol. 21, 2883–2886 (1991).
Munoz, C. et al. Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur. J. Immunol. 21, 2177–2184 (1991).
Andrejko, K.M. & Deutschman, C.S. Acute-phase gene expression correlates with intrahepatic tumor necrosis factor alpha abundance but not with plasma tumor necrosis factor concentrations during sepsis/systemic inflammatory response syndrome in the rat. Crit. Care Med. 24, 1947–1952 (1996).
Pellegrini, J.D., Puyana, J.C., Lapchak, P.H., Kodys, K. & Millergraziano, C.L. A membrane TNF-alpha/TNFR ratio correlates to MODS score and mortality. Shock 6, 389–396 (1996).
Wallach, D. A decade of accumulated knowledge and emerging answers. The 6th International Congress on TNF, Rhodes, Greece. May 1996. Eur. Cytokine Netw. 7, 713–724 (1996).
Vandenabeele, P., Declercq, W., Beyaert, R. & Fiers, W. Two tumor necrosis factor receptors: Structure and function. Tr. Cell Biol. 5, 392–399 (1995).
Evans, T.J. et al. Protective effect of 55-but not 75kD soluble tumor necrosis factor receptor immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180, 2173–2179 (1994).
Kwiatkowski, D. et al. Response to monoclonal anti-TNF antibody in children with cerebral malaria. Q. J. Med. 86, 91–98 (1993)
Brouckaert, P. et al. Inhibition of and sensitization to the lethal effects of tumor necrosis factor. J. Inflamm. 47, 18–26 (1996).
Döcke, W.D. et al. Monocyte deactivation in septic patients: Restoration by IFN-γ treatment. Nature Med. 3, 678–681 (1997).
About this article
Cite this article
Grau, G., Maennel, D. TNF inhibition and sepsis — sounding a cautionary note. Nat Med 3, 1193–1195 (1997). https://doi.org/10.1038/nm1197-1193
ABIN-1 is a key regulator in RIPK1-dependent apoptosis (RDA) and necroptosis, and ABIN-1 deficiency potentiates necroptosis-based cancer therapy in colorectal cancer
Cell Death & Disease (2021)
Pre-existing malignancy results in increased prevalence of distinct populations of CD4+ T cells during sepsis
PLOS ONE (2018)
Nature Reviews Drug Discovery (2018)
Mathematical Biosciences (2017)